

October 31, 2022
Web Announcement 2932

Drug Use Review (DUR) Board Approves Changes Effective October 31, 2022.

The Nevada Medicaid Drug Use Review (DUR) Board met on July 28, 2022, and voted to adopt the following changes effective October 31, 2022:

Drug Class/Program	Changes
Antipsychotics	Addition of new clinical criteria to Invega Hafyera® (paliperidone palmitate)
Antifungals	Addition of new clinical criteria to Brexafemme® (ibrexafungerp) Updates to existing criteria for Onychomycosis
Multiple Sclerosis Agents	Addition of new clinical criteria to Ponvory® (ponesimod)
Ileal Bile Acid Transport Inhibitor	Addition of new clinical criteria to Bylvay® (odevixibat) and Livmarli® (maralixibat)
Atopic Dermatitis Agents	Addition of new clinical criteria to Opzelura® (ruxolitinib)
Growth Hormones	Addition of new clinical criteria to Skytrofa® (lonapegsomatropin-tcgd)
Immediate-Release Fentanyl Products	Updates to existing clinical criteria
Ergot Derivatives	Addition of Trudhesa® (dihydroergotamine) to clinical criteria

Prior Authorization forms may be found on the pharmacy webpage
<https://nevadamedicaid.magellanrx.com/provider/forms>